Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eciskafusp alfa - Roche

Next Previous
Drug Profile

Eciskafusp alfa - Roche

Alternative Names: PD1-IL2v; RG 6279; RO-7284755

Latest Information Update: 04 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Class Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Interleukin 2 receptor agonists; Programmed cell death 1 receptor antagonists; Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 15 Jun 2025 Hoffmann-La Roche withdraws phase-I trial before enrollment in Bladder cancer (Combination therapy, Unresectable/Inoperable) in Australia, Italy, Malaysia, Netherlands, Poland and Spain (Intravesical) due to decision of the sponsor (NCT06816017)
  • 15 Feb 2025 Hoffmann-La Roche plans a phase I/II trial for Non-muscle invasive bladder cancer (Combination therapy, Inoperable/unresectable, Second-line therapy or greater, Recurrent) (Intravesical, Instillation) (NCT06816017)
  • 23 Aug 2023 Eciskafusp alfa is still in phase I trials for Solid tumours in Belgium, Canada, Denmark, Netherlands, Poland, Spain (SC) (IV) (Roche pipeline, August 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top